Physician profile
Sofia Haserot
NPI 1225626039
$3,825.44
in general payments reported to CMS, 2019-2025
27 companies · $1,222 in 2025
The $1,222 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $624 · 2023: $835 · 2024: $1,145 · 2025: $1,222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,201.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $649.85 | 2022-2025 | Repatha, Repatha, Tezspire |
| Novartis Pharmaceuticals Corporation | $523.03 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $386.36 | 2022-2025 | |
| Edwards Lifesciences Corporation | $309.35 | 2022-2025 | Sapien 3 Ultra Resilia |
| Ani Pharmaceuticals, INC. | $271.66 | 2023-2025 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $240.19 | 2022-2025 | Jardiance, Ofev, Spiriva Respimat |
| Novo Nordisk INC | $174.92 | 2024-2025 | Wegovy, Ozempic, Rivfloza |
| Mallinckrodt Hospital Products INC. | $147.32 | 2022-2025 | Acthar |
| Astrazeneca Pharmaceuticals Lp | $138.12 | 2022-2024 | Farxiga |
| Lilly USA, LLC | $118.54 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Verona Pharma, INC. | $114.26 | 2025 | Ohtuvayre |
| Glaxosmithkline, LLC. | $87.93 | 2023-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $85.96 | 2022-2023 | Jynarque |
| Kiniksa Pharmaceuticals International, Plc | $72.17 | 2024 | Arcalyst |
| Mylan Specialty L.P. | $59.83 | 2022-2024 | Yupelri |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $57.60 | 2024 | |
| Heartflow, INC. | $50.66 | 2025 | |
| Esperion Therapeutics, INC. | $50.49 | 2024-2025 | Nexletol |
| Ardelyx, INC. | $49.13 | 2023-2024 | Ibsrela |
| Horizon Therapeutics Plc | $47.36 | 2023 | Krystexxa |
| Kiniksa Pharmaceuticals, Ltd. | $44.64 | 2023 | Arcalyst |
| Exact Sciences Corporation | $42.37 | 2024-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $26.28 | 2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $24.37 | 2022 | |
| Boston Scientific Corporation | $20.85 | 2023 | Watchman Access System |
| Alnylam Pharmaceuticals INC. | $17.93 | 2023 | Amvuttra |
| Azurity Pharmaceuticals, INC. | $14.27 | 2023 | Edarbi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sofia Haserot listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.